Trichostatin A Protects Against Experimental Acute-on-Chronic Liver Failure in Rats Through Regulating the Acetylation of Nuclear Factor-κB

Inflammation

Volumn 38, Issue 3, 2015, Pages 1364-1373

  Zhang, Qian ^a   Yang, Fan ^a   Li, Xun ^a   Wang, Lu wen ^a   Chu, Xiao gang ^a   Zhang, Hong ^a   Gong, Zuo jiong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

acute on chronic liver failure; histone deacetylase; inflammation; nuclear factor B; Trichostatin A

Indexed keywords

GALACTOSAMINE; GAMMA INTERFERON; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INTERLEUKIN 10; INTERLEUKIN 18; LIPOPOLYSACCHARIDE; RELA PROTEIN, RAT; SERUM ALBUMIN; TRANSCRIPTION FACTOR RELA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; ACUTE-ON-CHRONIC LIVER FAILURE; ANIMAL; BLOOD; IMMUNOLOGY; INFLAMMATION; LIVER; METABOLISM; PATHOLOGY; RANDOMIZATION; RAT; WISTAR RAT;

ACETYLATION; ACUTE-ON-CHRONIC LIVER FAILURE; ANIMALS; GALACTOSAMINE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-18; LIPOPOLYSACCHARIDES; LIVER; RANDOM ALLOCATION; RATS; RATS, WISTAR; SERUM ALBUMIN; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939971490     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0108-7     Document Type: Article

References (50)

1. Jalan, R., and R. Williams. 2002. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 20(3): 252–261.
2. Wells, C.A., T. Ravasi, G.J. Faulkner, P. Carninci, Y. Okazaki, Y. Hayashizaki, M. Sweet, B.J. Wainwright, and D.A. Hume. 2003. Genetic control of the innate immune response BMC. Immunol 4: 5.
3. Wells, C.A., T. Ravasi, R. Sultana, K. Yagi, P. Carninci, H. Bono, G. Faulkner, Y. Okazaki, J. Quackenbush, D.A. Hume, and Lyons PA; RIKEN GER Group; GSL Members. 2003. Continued discovery of transcriptional units expressed in cells of the mouse mononuclear phagocyte lineage. Genome Res 13(6B): 1360–1365.
4. Byl, B., I. Roucloux, A. Crusiaux, E. Dupont, and J. Deviere. 1993. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 104: 1492–1497.
5. Le Moine, O., J. Devière, J.M. Devaster, A. Crusiaux, F. Durand, J. Bernuau, M. Goldman, and J.P. Benhamou. 1994. Interleukin-6: an early marker of bacterial infection indecompensated cirrhosis. J Hepatol 20: 819–824.
6. Navasa, M., A. Follo, X. Filella, W. Jiménez, A. Francitorra, R. Planas, A. Rimola, V. Arroyo, and J. Rodés. 1998. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 27(5): 1227–1232.
7. Genesca, J., A. Gonzalez, R. Segura, R. Catalan, R. Marti, E. Varela, G. Cadelina, M. Martinez, J.C. Lopez-Talavera, R. Esteban, R.J. Groszmann, and J. Guardia. 1999. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 94(1): 169–177.
8. Rodríguez-Ramos, C., F. Galan, F. Díaz, J. Elvira, L. Martín-Herrera, and J.A. Girón-González. 2001. Expression of pro-inflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitis. Dig Dis Sci 46(8): 1668–1676.
9. Albillos, A., L. Hera Ad Ade, E. Reyes, J. Monserrat, L. Muñoz, M. Nieto, A. Prieto, E. Sanz, and M. Alvarez-Mon. 2004. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: Amelioration with norfloxacin. J Hepatol 40: 624–631.
10. Rolando, N., J. Wade, M. Davalos, J. Wendon, J. Philpott-Howard, and R. Williams. 2000. The systemic inflammatory response syndrome in acute liver failure. Hepatology 32(4 Pt 1): 734–739.
11. Albillos, A., A. de la Hera, M. González, J.L. Moya, J.L. Calleja, J. Monserrat, L. Ruiz-del-Arbol, and M. Alvarez-Mon. 2003. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37(1): 208–217.
12. Harry, R., G. Auzinger, and J. Wendon. 2002. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 36: 395–402.
13. Kawai, T., and S. Akira. 2008. Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci 1143: 1–20.
14. Serhan, C.N., N. Chiang, and T.E. Van Dyke. 2008. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5): 349–361.
15. Berger, S.L. 2007. The complex language of chromatin regulation during transcription. Nature 447(7143): 407–412.
16. Dolinoy, D.C., J.R. Weidman, and R.L. Jirtle. 2007. Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod Toxicol 23(3): 297–307.
17. Jirtle, R.L., and M.K. Skinner. 2007. Environmental epigenomics and disease susceptibility. Nat Rev Genet 8(4): 253–262.
18. Khan, N., M. Jeffers, S. Kumar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S.C. Berghs, N. Carey, P.W. Finn, L.S. Collins, A. Tumber, J.W. Ritchie, P.B. Jensen, H.S. Lichenstein, and M. Sehested. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409(2): 581–589.
19. Blanchard, F., and C. Chipoy. 2005. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov Today 10(3): 197–204.
20. Gray, S.G., and T.J. Ekström. 2001. The human histone deacetylase family. Exp Cell Res 262(2): 75–83.
21. Lin, T., H.B. Alam, H. Chen, J. Britten-Webb, P. Rhee, J. Kirkpatrick, and E. Koustova. 2006. Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation. Surgery 139(3): 365–376.
22. Gonzales, E., H. Chen, R. Munuve, T. Mehrani, J. Britten-Webb, A. Nadel, H.B. Alam, D. Wherry, D. Burris, and E. Koustova. 2006. Valproic acid prevents hemorrhage-associated lethality and affects the acetylation pattern of cardiac histones. Shock 25(4): 395–401.
23. Li, Y., B. Liu, H. Zhao, E.A. Sailhamer, E.Y. Fukudome, X. Zhang, T. Kheirbek, R.A. Finkelstein, G.C. Velmahos, M. De Moya, C.A. Hales, and H.B. Alam. 2009. Protective effect of suberoylanilide hydroxamic acid against LPS-induced septic shock in rodents. Shock 32(5): 517–523.
24. Lin, T., H. Chen, E. Koustova, E.A. Sailhamer, Y. Li, C. Shults, B. Liu, P. Rhee, J. Kirkpatrick, and H.B. Alam. 2007. Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. Surgery 141(6): 784–794.
25. Cao, W., C. Bao, E. Padalko, and C.J. Lowenstein. 2008. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med 205(6): 1491–1503.
26. Zhang, L., J. Wan, R. Jiang, W. Wang, H. Deng, Y. Shen, W. Zheng, and Y. Wang. 2009. Protective effects of trichostatin A on liver injury in septic mice. Hepatol Res 39(9): 931–938.
27. Winkler, A.R., K.N. Nocka, and C.M. Williams. 2012. Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production. Pulm Pharmacol Ther 25(4): 286–292.
28. Wang, L.W., L.K. Wang, H. Chen, F. Cheng, X. Li, C.M. He, and Z.J. Gong. 2012. Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats. World J Gastroenterol 18(40): 5709–5718.
29. Yang, X.J., and E. Seto. 2008. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 31(4): 449–461.
30. Yang, X.J., and E. Seto. 2007. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37): 5310–5318.
31. Halili, M.A., M.R. Andrews, M.J. Sweet, and D.P. Fairlie. 2009. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 9(3): 309–319.
32. Okamoto, H., Y. Fujioka, A. Takahashi, T. Takahashi, T. Taniguchi, Y. Ishikawa, and M. Yokoyama. 2006. Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb 13(4): 183–191.
33. Yu, Z., W. Zhang, and B.C. Kone. 2002. Histone deacetylases augment cytokine induction of the iNOS gene. J Am Soc Nephrol 13(8): 2009–2017.
34. Suuronen, T., J. Huuskonen, R. Pihlaja, S. Kyrylenko, and A. Salminen. 2003. Regulation ofmicroglial inflammatory response by histone deacetylase inhibitors. J Neurochem 87(2): 407–416.
35. Moreau R, Arroyo V. Acute on chronic liver failure: a new clinical entity. Clin Gastroenterol Hepatol. 2014 Feb 28. [Epub ahead of print]
36. Li, X., L.K. Wang, L.W. Wang, X.Q. Han, F. Yang, and Z.J. Gong. 2013. Blockade of high-mobilitygroup box-1 ameliorates acute on chronic liver failure in rats. Inflamm Res 62(7): 703–709.
37. Zou, Z., B. Li, D. Xu, Z. Zhang, J.M. Zhao, G. Zhou, Y. Sun, L. Huang, J. Fu, Y. Yang, L. Jin, W. Zhang, J. Zhao, Y. Sun, S. Xin, and F.S. Wang. 2009. Imbalanced intrahepatic cytokine expression of interferon-gamma, tumor necrosis factor-alpha, and interleukin-10 in patients with acute-on-chronic liver failure associated with hepatitis B virus infection. J Clin Gastroenterol 43(2): 182–190.
38. Choi, J.H., S.W. Oh, M.S. Kang, H.J. Kwon, G.T. Oh, and D.Y. Kim. 2005. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 35(1): 89–96.
39. Glauben, R., A. Batra, I. Fedke, M. Zeitz, H.A. Lehr, F. Leoni, P. Mascagni, G. Fantuzzi, C.A. Dinarello, and B. Siegmund. 2006. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176(8): 5015–5022.
40. Lin, H.S., C.Y. Hu, H.Y. Chan, et al. 2007. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collageninduced arthritis in rodents. Br J Pharmacol 150: 862–872.
41. Berger, S.L. 2002. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12(2): 142–148.
42. Marinova, Z., M. Ren, J.R. Wendland, Y. Leng, M.H. Liang, S. Yasuda, P. Leeds, and D.M. Chuang. 2009. Valproic acid induces functional heat-shock protein 70 via class I histonedeacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 111(4): 976–987.
43. Nasu, Y., K. Nishida, S. Miyazawa, T. Komiyama, Y. Kadota, N. Abe, A. Yoshida, S. Hirohata, A. Ohtsuka, and T. Ozaki. 2008. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in acollagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 16(6): 723–732.
44. Sailhamer, E.A., Y. Li, E.J. Smith, F. Shuja, C. Shults, B. Liu, C. Soupir, M. De Moya, G. Velmahos, and H.B. Alam. 2008. Acetylation: a novel method for modulation of the immune response following trauma/hemorrhage and inflammatory second hit in animals and humans. Surgery 144(2): 204–216.
45. Leoni, F., G. Fossati, E.C. Lewis, J.K. Lee, G. Porro, P. Pagani, D. Modena, M.L. Moras, P. Pozzi, L.L. Reznikov, B. Siegmund, G. Fantuzzi, C.A. Dinarello, and P. Mascagni. 2005. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11(1–12): 1–15.
46. Choudhary, C., C. Kumar, F. Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, J.V. Olsen, and M. Mann. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942): 834–840.
47. McKinsey, T.A., and E.N. Olson. 2004. Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found Symp 259: 132–141.
48. Cao, W., C. Bao, E. Padalko, and C.J. Lowenstein. 2008. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits toll-like receptor signaling. J Exp Med 205: 1491–1503.
49. Chen, L., W. Fischle, E. Verdin, and W.C. Greene. 2001. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653–1657.
50. Chen, L.F., and W.C. Greene. 2003. Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med 81: 549–557.